APRIL — Springtime for New IgA Nephropathy Therapy?

Kevin V. Lemley,Richard J. Glassock

DOI: https://doi.org/10.1056/nejme2312300

IF: 158.5

2024-01-05

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 390, Issue 1, Page 80-81, January 2024.

medicine, general & internal

What problem does this paper attempt to address?

Targeting APRIL to slow progression of IgA nephropathy

Monica Wang

DOI: https://doi.org/10.1038/s41581-023-00794-x

IF: 42.439

2023-11-28

Nature Reviews Nephrology

Abstract:TNF family ligands such as a proliferation-inducing ligand (APRIL) promote B cell expansion and survival. New clinical trial data presented at ASN Kidney Week 2023 suggest that targeting APRIL might be therapeutic in IgA nephropathy (IgAN).

urology & nephrology
New Insights and Future Perspectives of APRIL in IgA Nephropathy

Masahiro Muto,Hitoshi Suzuki,Yusuke Suzuki

DOI: https://doi.org/10.3390/ijms251910340

IF: 5.6

2024-09-27

International Journal of Molecular Sciences

Abstract:IgA nephropathy (IgAN) is characterized by immune-mediated glomerulonephritis, with the accumulation of galactose-deficient IgA1 (Gd-IgA1) in the glomeruli and increased levels of circulating Gd-IgA1 and Gd-IgA1-containing immune complexes. An incomplete understanding of the underlying mechanisms and differences in clinical and pathological features between individuals and ethnicities has contributed to the lack of established treatments for IgAN. A tumor necrosis factor (TNF) family member, a proliferation-inducing ligand (APRIL), is a crucial cytokine essential for the generation and survival of plasma cells. Recent studies demonstrated that APRIL is a pivotal mediator in the production of Gd-IgA1 in IgAN. As our understanding of the autoimmune pathogenesis underlying IgAN has improved, various pharmacological therapeutic targets, including APRIL antagonists, have emerged. Preliminary results showed that APRIL-targeting agents effectively reduced proteinuria and Gd-IgA1 levels without significantly increasing adverse events, indicating their potential as novel therapeutic agents for IgAN. In the present review, we discuss the current understanding of the role of APRIL in the pathogenesis of IgAN and novel therapeutic strategies focusing on APRIL-targeting agents for IgAN. APRIL inhibitors may offer new hope to patients with IgAN.

biochemistry & molecular biology,chemistry, multidisciplinary
Targeting APRIL in the treatment of glomerular diseases

Chee Kay Cheung,Jonathan Barratt,Richard Lafayette,Adrian Liew,Yusuke Suzuki,Vladimír Tesař,Hernán Trimarchi,Muh Geot Wong,Hong Zhang,Dana V Rizk

DOI: https://doi.org/10.1016/j.kint.2024.08.012

2024-08-23

Abstract:A PRoliferation Inducing Ligand (APRIL) is a key member of the tumor necrosis factor (TNF)-superfamily of cytokines, and plays a central role in B cell survival, proliferation and immunoglobulin class switching. Recently, there has been increasing interest in the role of APRIL and the related cytokine B cell activating factor (BAFF) in several glomerular diseases, due to their importance in the above processes. The therapeutic inhibition of APRIL represents a potentially attractive immunomodulatory approach, that may abrogate deleterious host immune responses in autoimmune diseases while leaving other important functions of humoral immunity intact, such as memory B cell function and responses to vaccination, in contrast to B cell depleting strategies. In this review, we describe the physiological roles of APRIL in B cell development and their relevance to glomerular diseases, and outline emerging clinical trial data studying APRIL inhibition, with a focus on IgA nephropathy where the clinical development of APRIL inhibitors is in its most advanced stage.
New Horizons in IgA Nephropathy: A Focus on Current Treatment and Emerging Solutions

Eleanor Roberts

DOI: https://doi.org/10.33590/emj/10303661

2023-12-14

European Medical Journal

Abstract:IgA nephropathy (IgAN) is a common form of glomerular disease, with wide heterogeneity of symptom occurrence and progression. Diagnosis is based on kidney biopsy findings. IgAN initiates in the mucosa with development of galactose-deficient IgA1 (Gd-IgA1) and anti-Gd-IgA1 autoantibodies, leading to deposition of these complexes in glomerular mesangium with resulting fibrosis, inflammation, tubulointerstitial scarring, and glomerular injury. This can lead to chronic kidney disease (CKD), kidney failure, and death. IgAN treatment involves optimised supportive care, including individualised strategies to address symptoms, such as high blood pressure control and cardiovascular risks. Drug treatment includes renin-angiotensin-aldosterone system (RAAS) inhibitors and immunosuppressant therapies. While the latter can successfully lower proteinuria, and have a positive effect on estimated glomerular filtration rate (eGFR), adverse effects can limit treatment duration, and increasing proteinuria and decreasing eGFR can return following treatment discontinuation. New formulations of immunosuppressant therapies include delayed-release budesonide with targeted release in the lower part of the small intestine where Gd-IgA1 production occurs. Although treatment with this drug can reduce proteinuria and sustain eGFR levels, similar to other immunosuppressant therapies, effects seem to be predominantly limited to the active treatment period. Targeting a different mechanism, sparsentan is a dual endothelin A receptor (ETA) and angiotensin II receptor type 1 (AT1) blocker that targets endothelin-1 (ET-1) and angiotensin II, both involved in IgAN progression. Initial Phase III trial results show significant differences, favouring sparsentan, compared with the AT1 blocker irbesartan, on proteinuria, with similar adverse event profiles. These agents, and several other drugs in development, will widen the armamentarium of therapies for people with IgAN, which, when used in combination, can target different aspects of IgAN pathogenesis for a more individualised treatment approach.
Advances in the treatment of IgA nephropathy with biological agents

Yongze Zhuang,Hailing Lu,Junxia Li

DOI: https://doi.org/10.1002/cdt3.104

2023-12-10

Abstract:Immunoglobulin A nephropathy (IgAN) is the most common primary glomerular disease, and the "four-hit" theory represents its currently accepted pathogenic mechanism. Mucosal immunity triggered by infections in the respiratory tract, intestines, or other areas leads to antigen presentation, T cell stimulation, B cell maturation, and the production of IgA-producing plasma cells. The proteins B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) are involved in this process, and alternative complement and lectin pathway activation are also part of the pathogenic mechanism. Kidney Disease Improving Global Outcomes guidelines indicate that a specific effective treatment for IgAN is lacking, with renin-angiotensin-aldosterone system inhibitors being the primary therapy. Recent research shows that biological agents can significantly reduce proteinuria, stabilize the estimated glomerular filtration rate, and reverse some pathological changes, such as endocapillary proliferation and crescent formation. There are four main categories of biological agents used to treat IgA nephropathy, specifically anti-CD20 monoclonal antibodies, anti-BLyS or APRIL monoclonal antibodies, monoclonal antibodies targeting both BLyS and APRIL (telitacicept and atacicept), and monoclonal antibodies inhibiting complement system activation (narsoplimab and eculizumab). However, further research on the dosages, treatment duration, long-term efficacy, and safety of these biological agents is required.
An Update on Current Therapeutic Options in IgA Nephropathy

Regina Shaoying Lim,See Cheng Yeo,Jonathan Barratt,Dana V. Rizk

DOI: https://doi.org/10.3390/jcm13040947

IF: 3.9

2024-02-08

Journal of Clinical Medicine

Abstract:Immunoglobulin A nephropathy (IgAN) remains the leading cause of primary glomerular disease worldwide. Outcomes are poor with high rates of progressive chronic kidney disease and kidney failure, which contributes to global healthcare costs. Although this disease entity has been described, there were no disease-specific treatments until recently, with the current standard of care focusing on optimal supportive measures including lifestyle modifications and optimization of the renin-angiotensin-aldosterone blockade. However, with significant advances in the understanding of the pathogenesis of IgAN in the past decade, and the acceptance of surrogate outcomes for accelerated drug approval, there have been many new investigational agents tested to target this disease. As these agents become available, we envision a multi-pronged treatment strategy that simultaneously targets the consequences of ongoing nephron loss, stopping any glomerular inflammation, inhibiting pro-fibrotic signals in the glomerulus and tubulo-interstitium, and inhibiting the production of pathogenic IgA molecules. This review is an update on a previous review published in 2021, and we aim to summarize the developments and updates in therapeutic strategies in IgAN and highlight the promising discoveries that are likely to add to our armamentarium.

medicine, general & internal
Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy

DOI: https://doi.org/10.1056/nejmc2401277

IF: 158.5

2024-04-05

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 390, Issue 13, Page 1245-1246, April 2024.

medicine, general & internal
A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy

James R Myette,Toshiki Kano,Hitoshi Suzuki,Susan E Sloan,Kristy J Szretter,Boopathy Ramakrishnan,Hedy Adari,Ketan D Deotale,Frank Engler,Zachary Shriver,Andrew M Wollacott,Yusuke Suzuki,Brian J G Pereira

DOI: https://doi.org/10.1016/j.kint.2019.01.031

Abstract:IgA nephropathy (IgAN) is the most prevalent primary chronic glomerular disease for which no safe disease-specific therapies currently exist. IgAN is an autoimmune disease involving the production of autoantigenic, aberrantly O-glycosylated IgA1 and ensuing deposition of nephritogenic immune complexes in the kidney. A Proliferation Inducing Ligand (APRIL) has emerged as a key B-cell-modulating factor in this pathogenesis. Using a mouse anti-APRIL monoclonal antibody (4540), we confirm both the pathogenic role of APRIL in IgAN and the therapeutic efficacy of antibody-directed neutralization of APRIL in the grouped mouse ddY disease model. Treatment with 4540 directly translated to a reduction in relevant pathogenic mechanisms including suppressed serum IgA levels, reduced circulating immune complexes, significantly lower kidney deposits of IgA, IgG and C3, and suppression of proteinuria compared to mice receiving vehicle or isotype control antibodies. Furthermore, we translated these findings to the pharmacological characterization of VIS649, a highly potent, humanized IgG2κ antibody targeting and neutralizing human APRIL through unique epitope engagement, leading to inhibition of APRIL-mediated B-cell activities. VIS649 treatment of non-human primates showed dose-dependent reduction of serum IgA levels of up to 70%. A reduction of IgA+, IgM+, and IgG+ B cells was noted in the gut-associated mucosa of VIS649-treated animals. Population-based modeling predicted a favorable therapeutic dosing profile for subcutaneous administration of VIS649 in the clinical setting. Thus, our data highlight the potential therapeutic benefit of VIS649 for the treatment of IgAN.
Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy

Sheila A. Doggrell

DOI: https://doi.org/10.1080/14712598.2024.2346111

2024-04-27

Expert Opinion on Biological Therapy

Abstract:Introduction Immunoglobulin A (IgA) nephropathy is a common immune-mediated kidney disease leading to high blood pressure and may progress to kidney failure. None of the present treatments are disease-modifying or prolong life. The levels of A PRoliferation Inducing Ligand (APRIL) are raised in subjects with IgA nephropathy. Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to, and neutralizes, APRIL.

medicine, research & experimental,biotechnology & applied microbiology
Advances in Treatment of IgA Nephropathy

JIA Xiao-yuan,WANG Wei-ming

DOI: https://doi.org/10.3969/j.issn.1674-8115.2012.03.027

2012-01-01

Abstract:IgA nephropathy(IgAN) is the most common glomerulus disease in the world,and IgAN accounts for 45.2% to 58.2% of primary glomerulonephritis in China.The pathogenesis of IgAN remains unknown,and angiotensin converting enzyme inhibitor(ACEI)/angiotensin Ⅱ receptor blocker(ARB),corticosteroid and immunosuppressive agents are widely used in clinics.However,there has been no unified standard in IgAN therapy.In 2010 Renal Week of American Society of Nephrology(ASN),Kidney Disease Improving Global Outcomes(KDIGO) put forward suggestions on the treatment of IgAN based on evidence-based medicine.In this paper,these suggestions are reviewed.
New therapies for immunoglobulin A nephropathy: what's the standard of care in 2023?

Bryce Barr,Sean Barbour

DOI: https://doi.org/10.1097/mnh.0000000000000979

2024-03-20

Current Opinion in Nephrology & Hypertension

Abstract:As the most common primary glomerulonephritis, immunoglobulin A (IgA) nephropathy (IgAN) is an important cause of kidney failure and mortality. Until recently, therapeutic options were limited. Fortunately, there have been numerous recent clinical trials demonstrating efficacy of new therapies in slowing chronic kidney disease (CKD) progression at varying stages of disease.

peripheral vascular disease,urology & nephrology
The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy

See Cheng Yeo,Jonathan Barratt

DOI: https://doi.org/10.1093/ckj/sfad200

2023-12-04

Abstract:Advances in our understanding of the pathogenesis of immunoglobulin A nephropathy (IgAN) have led to the identification of novel therapeutic targets and potential disease-specific treatments. Specifically, a proliferation-inducing ligand (APRIL) has been implicated in the pathogenesis of IgAN, mediating B-cell dysregulation and overproduction of pathogenic galactose-deficient IgA1 (Gd-IgA1). Animal and clinical studies support the involvement of APRIL in the pathogenesis and progression of IgAN. An elevated level of APRIL is found in IgAN when compared with controls, which correlates with the level of Gd-IgA1 and associates with more severe disease presentation and worse outcomes. Conversely, anti-APRIL therapy reduces pathogenic Gd-IgA1 and IgA immune complex formation and ameliorates the severity of kidney inflammation and injury. Genome-wide association studies in IgAN have identified TNFSF13 and TNFRSF13B, a cytokine ligand-receptor gene pair encoding APRIL and its receptor, respectively, as risk susceptibility loci in IgAN, further supporting the causal role of the APRIL signalling pathway in IgAN. Several novel experimental agents targeting APRIL, including atacicept, telitacicept, zigakibart and sibeprenlimab, are currently under investigation as potential therapies in IgAN. Preliminary results suggest that these agents are well-tolerated, and reduce levels of Gd-IgA1, with corresponding improvement in proteinuria. Further studies are ongoing to confirm the safety and efficacy of anti-APRIL approaches as an effective therapeutic strategy in IgAN.
Efficacy of Rituximab for Patients with Anti-Glomerular Basement Membrane Disease.

Liangliang Chen,Yiting Chen,Anqi Ni,Yuxin Lin,Xiaoqi Shen,Jianghua Chen,Fei Han

DOI: https://doi.org/10.1093/ndt/gfad268

IF: 7.1857

2024-01-01

Nephrology Dialysis Transplantation

Abstract:Journal Article Corrected proof Efficacy of rituximab for patients with anti-glomerular basement membrane disease Get access Liangliang Chen, Liangliang Chen Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaInstitute of Nephrology, Zhejiang University, Hangzhou, Zhejiang, ChinaKey Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province, Hangzhou, Zhejiang, ChinaZhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, Zhejiang, China Search for other works by this author on: Oxford Academic PubMed Google Scholar Yiting Chen, Yiting Chen Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaInstitute of Nephrology, Zhejiang University, Hangzhou, Zhejiang, ChinaKey Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province, Hangzhou, Zhejiang, ChinaZhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, Zhejiang, China Search for other works by this author on: Oxford Academic PubMed Google Scholar Anqi Ni, Anqi Ni Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaInstitute of Nephrology, Zhejiang University, Hangzhou, Zhejiang, ChinaKey Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province, Hangzhou, Zhejiang, ChinaZhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, Zhejiang, China Search for other works by this author on: Oxford Academic PubMed Google Scholar Yuxin Lin, Yuxin Lin Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaInstitute of Nephrology, Zhejiang University, Hangzhou, Zhejiang, ChinaKey Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province, Hangzhou, Zhejiang, ChinaZhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, Zhejiang, China Search for other works by this author on: Oxford Academic PubMed Google Scholar Xiaoqi Shen, Xiaoqi Shen Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaInstitute of Nephrology, Zhejiang University, Hangzhou, Zhejiang, ChinaKey Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province, Hangzhou, Zhejiang, ChinaZhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, Zhejiang, China Search for other works by this author on: Oxford Academic PubMed Google Scholar Jianghua Chen, Jianghua Chen Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaInstitute of Nephrology, Zhejiang University, Hangzhou, Zhejiang, ChinaKey Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province, Hangzhou, Zhejiang, ChinaZhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, Zhejiang, China https://orcid.org/0000-0001-5958-8177 Search for other works by this author on: Oxford Academic PubMed Google Scholar Fei Han Fei Han Kidney Disease Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, ChinaInstitute of Nephrology, Zhejiang University, Hangzhou, Zhejiang, ChinaKey Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province, Hangzhou, Zhejiang, ChinaZhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou, Zhejiang, China Correspondence to: Fei Han; E-mail: hanf8876@zju.edu.cn https://orcid.org/0000-0001-5363-7556 Search for other works by this author on: Oxford Academic PubMed Google Scholar Nephrology Dialysis Transplantation, gfad268, https://doi.org/10.1093/ndt/gfad268 Published: 21 December 2023 Article history Received: 31 October 2023 Published: 21 December 2023 Corrected and typeset: 13 January 2024
State-of-Art Therapeutics in IgA Nephropathy

Mohit Mathur,Manisha Sahay,Brian J G Pereira,Dana V Rizk

DOI: https://doi.org/10.25259/ijn_319_23

Abstract:Immunoglobulin-A nephropathy (IgAN) is the most common primary glomerulonephritis in the world, with up to 40% of patients progressing to end-stage kidney disease (ESKD) within 30 years of diagnosis. IgAN is characterized by elevated serum levels of galactose-deficient IgA1 (Gd-IgA1), which leads to immune complex formation and deposition in the glomerular mesangium, causing kidney injury. A diverse disease course and the long-term follow-up required for clinically relevant endpoints (e.g., ESKD) have been barriers to the development of novel therapies in IgAN. Disease management has focused on supportive care with inhibitors of the renin-angiotensin system and, more recently, sodium-glucose transporter inhibitors to control proteinuria. The recent acceptance of proteinuria as a surrogate endpoint by regulatory bodies and a better understanding of disease pathology have helped to initiate the development of several novel treatments. Subsequently, a targeted-release formulation of budesonide and a dual endothelin/angiotensin inhibitor (sparsentan) have received accelerated approval for patients with IgAN. However, additional therapies are needed to target the different pathogenic mechanisms and individualize patient care. Several compounds currently under investigation target various effectors of pathology. There are promising clinical results from emerging compounds that target the generation of Gd-IgA1 by B cells, including inhibitors of A PRoliferation-Inducing Ligand (APRIL) and dual inhibitors of APRIL and B-cell activating factor (BAFF). Other investigational therapies target the complement cascade by inhibiting proteins of the lectin or alternative pathways. As the therapeutic landscape evolves, it will be important to revise treatment guidelines and develop updated standards of care.
Functional networks of aging markers in the glomeruli of IgA nephropathy: a new therapeutic opportunity.

Hong Jiang,Ludan Liang,Jing Qin,Yingying Lu,Bingjue Li,Yucheng Wang,Chuan Lin,Qin Zhou,Shi Feng,Shun H Yip,Feng Xu,En Yin Lai,Junwen Wang,Jianghua Chen

DOI: https://doi.org/10.18632/oncotarget.9033

2016-01-01

Oncotarget

Abstract:IgA nephropathy(IgAN) is the most common primary glomerular disease in China. Primary infections always occur before IgAN. However, the pathology of IgAN is still unclear. Previously we found that LL37, a protein secreted by senescent cells, was specific for the progression of IgAN, and also played a role in the neutrophil function. So we hypothesized that the infiltration of neutrophils, inflammation factors, and aging markers, which were modulated by functional networks, induced the immune response and renal injury. RNA-Sequencing (RNA-seq) can be used to study the whole transcriptome and detect splicing variants that are expressed in a specific cell type or tissue. We separate glomerulus from the renal biopsy tissues. After RNA extraction, the sequences were analyzed with Illumina HiSeq 2000/2500. 381 genes with differential expression between the IgAN patients and the healthy controls were identified. Only PLAU, JUN, and FOS were related to DNA damage, telomere dysfunction-induced aging markers, neutrophil function and IgA nephropathy. The networks showed the possibility of these genes being connected. We conclude that DNA damage and telomere dysfunction could play important roles in IgA nephropathy. In addition, neutrophils are also important factors in this disease. The networks of these markers showed the mechanism pathways that are involved in the duration of the occurrence and progression of IgA nephropathy and might be a new therapeutic opportunity for disease treatment.
Therapy of IgA nephropathy: time for a paradigm change

Jonathan Barratt,Richard A Lafayette,Jürgen Floege

DOI: https://doi.org/10.3389/fmed.2024.1461879

2024-08-15

Abstract:Immunoglobulin A nephropathy (IgAN) often has a poor outcome, with many patients reaching kidney failure within their lifetime. Therefore, the primary goal for the treatment of IgAN should be to reduce nephron loss from the moment of diagnosis. To achieve this, IgAN must be recognized and treated as both a chronic kidney disease and an immunological disease. Agents that have received US Food and Drug Administration and European Medicines Agency approval for the treatment of IgAN include modified-release/targeted-release formulation budesonide (Nefecon) and sparsentan, a selective dual endothelin-A and angiotensin II receptor type 1 antagonist. Other agents, including selective endothelin receptor antagonists, selective or combined APRIL and BAFF antagonists, and a vast array of complement inhibitors are being investigated for the treatment of IgAN. Furthermore, treatment combinations are also being studied, including sodium-glucose cotransporter-2 inhibitors with endothelin receptor antagonists. Due to the complexity of IgAN, combination treatment, rather than a single-agent approach, may provide maximum benefit. With the number of treatments for IgAN likely to increase, combinations allowing safe and effective treatment to halt progression to kidney failure seem within grasp. While trials evaluating combinations are ongoing, more are needed to pave the way for a comprehensive IgAN treatment strategy. Furthermore, an approach to IgAN treatment in which agents are combined early to achieve rapid induction of remission and prevent unnecessary and irreversible nephron loss is required. Following remission, treatments may be adjusted and stripped back as necessary in the maintenance phase with close monitoring. This review discusses the current status of IgAN treatment and explores future strategies to improve outcomes for patients with IgAN.
IgA Nephropathy: Current Treatment and New Insights

Dimitra Petrou,Petros Kalogeropoulos,George Liapis,Sophia Lionaki

DOI: https://doi.org/10.3390/antib12020040

2023-06-19

Abstract:IgA Nephropathy (IgAN) is the most common cause of primary glomerulonephritis worldwide. Despite the histopathologic hallmark of mesangial IgA deposition, IgAN is a heterogenous autoimmune disease not only in terms of clinical presentation but also in long-term disease progression. The pathogenesis of the disease is complex and includes the generation of circulating IgA immune complexes with chemical and biological characteristics that favor mesangial deposition and reaction to mesangial under-glycosylated IgA1 accumulation, which leads to tissue injury with glomerulosclerosis and interstitial fibrosis. Patients with proteinuria over 1 g, hypertension, and impaired renal function at diagnosis are considered to be at high risk for disease progression and end-stage kidney disease (ESKD). Glucocorticoids have been the mainstay of treatment for these patients for years, but without long-term benefit for renal function and accompanied by several adverse events. A better understanding of the pathophysiology of IgAN in recent years has led to the development of several new therapeutic agents. In this review, we summarize the current therapeutic approach for patients with IgAN as well as all novel investigational agents.
[Diagnosis and Treatment of IgA Nephropathy-2023]

Judith Schimpf,Andreas Kronbichler,Martin Windpessl,Emanuel Zitt,Kathrin Eller,Marcus D Säemann,Karl Lhotta,Michael Rudnicki

DOI: https://doi.org/10.1007/s00508-023-02257-6

Abstract:Immunoglobulin A nephropathy (IgAN) is the most common glomerulonephritis. It leads to end-stage kidney disease in about a third of the patients within 10 to 20 years. The pathogenesis of IgAN is incompletely understood. It is believed that a dysregulation of the mucosal immune system leads to undergalactosylation of IgA, followed by formation of IgG autoantibodies against undergalactosylated IgA, circulation of these IgG-IgA immune complexes, deposition of the immune complexes in the mesangium, ultimately resulting in glomerular inflammation. IgAN can occasionally be triggered by other diseases, these secondary causes of IgAN should be identified or ruled out (chronic inflammatory bowel disease, infections, tumors, rheumatic diseases). Characteristic findings of IgAN of variable extent are a nephritic urinary sediment (erythrocytes, acanthocytes, erythrocyte casts), proteinuria, impaired renal function, arterial hypertension, or intermittent painless macrohematuria, especially during infections of the upper respiratory tract. However, the diagnosis of IgAN can only be made by a kidney biopsy. A histological classification (MEST‑C score) should always be reported to be able to estimate the prognosis. The most important therapeutic measure is an optimization of the supportive therapy, which includes, among other things, a consistent control of the blood pressure, an inhibition of the RAS, and the administration of an SGLT2 inhibitor. A systemic immunosuppressive therapy with corticosteroids is discussed controversially, should be used restrictively and only administered after an individual benefit-risk assessment under certain conditions that speak for a progressive IgAN. New promising therapeutics are enteral Budesonide or the dual angiotensin-II-receptor- and endothelin-receptor-antagonist Sparsentan. Rapidly progressive IgAN should be treated with corticosteroids and cyclophosphamide like ANCA-associated vasculitis.
Glomerular diseases: emerging tests and therapies for IgA nephropathy

Pietro A Canetta,Krzysztof Kiryluk,Gerald B Appel

DOI: https://doi.org/10.2215/CJN.07260713

Abstract:The last decade has seen major progress in understanding the pathogenesis as well as the prognosis and treatment of patients with IgA nephropathy (IgAN). Although the diagnostic criterion of a kidney biopsy demonstrating dominant or codominant IgA deposition remains unchanged, much more is known about the genetic and environmental factors predisposing to disease development and progression. These advances have led to the identification of novel diagnostic and prognostic markers. Among the most promising clinically are genetic profiling, quantification of galactose-deficient IgA1 levels, and measurement of anti-IgA1 immunoglobulins. While targeted treatment for IgAN remains elusive, there is mounting evidence for therapeutic interventions that alter the disease course. The appropriate validation and integration of these discoveries into clinical care represent a major challenge, but one that holds tremendous promise for refining prognostication, guiding therapy, and improving the lives of patients with IgAN.
Drugs in Development to Treat IgA Nephropathy

Lucia Del Vecchio,Marco Allinovi,Stefania Comolli,Silvia Peiti,Chiara Rimoldi,Francesco Locatelli

DOI: https://doi.org/10.1007/s40265-024-02036-1

2024-05-24

Drugs

Abstract:IgA nephropathy is a common glomerulonephritis consequent to the autoimmune response to aberrant glycosylated immunoglobulin (Ig) A antibodies. Although it has historically been considered a benign disease, it has since become clear that a substantial percentage of patients reach end-stage kidney failure over the years. Several therapeutic attempts have been proposed, with systemic steroids being the most prevalent, albeit burdened by possible serious adverse events. Thanks to the more in-depth knowledge of the pathogenesis of IgA nephropathy, new treatment targets have been identified and new drugs developed. In this narrative review, we summarise the molecules under clinical development for the treatment of IgA nephropathy. As a search strategy, we used PubMed, Google, ClinicalTrials.gov and abstracts from recent international congresses. TRF budesonide and sparsentan are the two molecules at a more advanced stage, just entering the market. Other promising agents are undergoing phase III clinical development. These include anti-APRIL and anti-BLyS/BAFF antibodies and some complement inhibitors. Other new possible strategies include spleen tyrosine kinase inhibitors, anti-CD40 ligands and anti-CD38 antibodies. In an era increasingly characterised by 'personalised medicine' and 'precision therapy' approaches and considering that the potential therapeutic armamentarium for IgA nephropathy will be very broad in the near future, the identification of biomarkers capable of helping the nephrologist to select the right drug for the right patient should be the focus of future studies.

pharmacology & pharmacy,toxicology

APRIL — Springtime for New IgA Nephropathy Therapy?

Targeting APRIL to slow progression of IgA nephropathy

New Insights and Future Perspectives of APRIL in IgA Nephropathy

Targeting APRIL in the treatment of glomerular diseases

New Horizons in IgA Nephropathy: A Focus on Current Treatment and Emerging Solutions

Advances in the treatment of IgA nephropathy with biological agents

An Update on Current Therapeutic Options in IgA Nephropathy

Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy

A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy

Sibeprenlimab, which neutralizes A PRoliferation Inducing Ligand (APRIL), as a new approach to treating IgA nephropathy

Advances in Treatment of IgA Nephropathy

New therapies for immunoglobulin A nephropathy: what's the standard of care in 2023?

The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy

Efficacy of Rituximab for Patients with Anti-Glomerular Basement Membrane Disease.

State-of-Art Therapeutics in IgA Nephropathy

Functional networks of aging markers in the glomeruli of IgA nephropathy: a new therapeutic opportunity.

Therapy of IgA nephropathy: time for a paradigm change

IgA Nephropathy: Current Treatment and New Insights

[Diagnosis and Treatment of IgA Nephropathy-2023]

Glomerular diseases: emerging tests and therapies for IgA nephropathy

Drugs in Development to Treat IgA Nephropathy